Bayforest Capital Ltd Makes New Investment in Masimo Corporation $MASI

Bayforest Capital Ltd purchased a new position in Masimo Corporation (NASDAQ:MASI) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,705 shares of the medical equipment provider’s stock, valued at approximately $1,128,000. Masimo makes up about 0.5% of Bayforest Capital Ltd’s portfolio, making the stock its 20th largest holding.

Other institutional investors have also modified their holdings of the company. Twin Tree Management LP acquired a new position in shares of Masimo in the first quarter worth $29,000. Farther Finance Advisors LLC grew its stake in shares of Masimo by 128.9% during the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 116 shares in the last quarter. Hilltop National Bank acquired a new position in shares of Masimo during the second quarter worth $37,000. Anderson Financial Strategies LLC acquired a new position in shares of Masimo during the first quarter worth $49,000. Finally, Quarry LP grew its stake in shares of Masimo by 253.5% during the first quarter. Quarry LP now owns 449 shares of the medical equipment provider’s stock worth $75,000 after purchasing an additional 322 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Performance

NASDAQ:MASI opened at $148.01 on Tuesday. The firm’s 50 day moving average is $145.76 and its two-hundred day moving average is $155.04. Masimo Corporation has a fifty-two week low of $133.70 and a fifty-two week high of $194.88. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. The company has a market cap of $8.04 billion, a P/E ratio of -17.37 and a beta of 1.28.

Masimo (NASDAQ:MASI) last issued its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business had revenue of $617.00 million for the quarter. Analysts expect that Masimo Corporation will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MASI. Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Piper Sandler boosted their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Wall Street Zen raised Masimo from a “hold” rating to a “buy” rating in a report on Tuesday. Zacks Research raised Masimo from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, BTIG Research reissued a “buy” rating and issued a $198.00 target price on shares of Masimo in a report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $194.60.

Insider Transactions at Masimo

In other news, Director William R. Jellison bought 3,000 shares of Masimo stock in a transaction on Monday, August 11th. The stock was purchased at an average cost of $145.98 per share, with a total value of $437,940.00. Following the purchase, the director directly owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This trade represents a 167.60% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 16.90% of the stock is owned by insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.